CDKN2A - melanoma-pancreatic cancer syndrome ¹

This test is available for the following conditions:

  • Conditions > Skin > Melanoma-pancreatic cancer syndrome
  • Conditions > Oncogenetics > Melanoma-pancreatic cancer syndrome

This product is also part of the following panels:

  • panel Melanoma, basic (CDKN2A, CDK4, MITF p.(Glu318Lys)¹
  • panel Melanoma, basic (CDKN2A, CDK4, MITF p.(Glu318Lys)¹
  • panel Melanoma, extensive (CDKN2A, CDK4, MITF p.(Glu318Lys), BAP1, POT1, TERT promoter)¹
  • panel Melanoma, extensive (CDKN2A, CDK4, MITF p.(Glu318Lys), BAP1, POT1, TERT promoter)¹
  • WES hereditary cancer (% *)
  • WES Mendelian inherited disorders (% *)
  • WES skin disorders¹ (% *)

* % of the coding region of this gene has a coverage of >20x. (Without % information : This is a non-coding gene for which coverage statistics could not be determined)

Turnaround time
Complete analysis: 8 weeks / Targeted analysis: 4 weeks

Method

  • Sequence analysis of all coding exons and flanking intron-exon boundaries

OMIM: 600160
Performing laboratory: Maastricht UMC+
Authorized material(s): EDTA blood, Isolated DNA, Buccal mucous membrane




€ 352

Gene

CDKN2A - melanoma-pancreatic cancer syndrome ¹

Turnaround time
Complete analysis: 8 weeks / Targeted analysis: 4 weeks
Performing laboratory
Maastricht UMC+
€ 352

CDKN2A - melanoma-pancreatic cancer syndrome ¹



€ 352